Biomedical cell products in patients with diabetic foot syndrome using feasibility (literature review)

Abstract

Today, the rapid and cost-effective treatment of patients with diabetic foot syndrome (DFS) is still challenging. The use of biomedical cell products (BCP) in this patients category has a clear pathogenetic orientation, but it remains not fully understood and generally accepted. The review presents the results of numerous studies confirming the efficacy of BCP for the treatment of predominantly superficial trophic defects in patients with neuropathic DFS. However, these technologies are still classified as adjuvant therapies. There are no clear algorithms and regulations for the use of BCP. It has been shown that their use accelerates the reparative processes in superficial trophic defects in patients with neuropathic DFS in combination with standard therapy and shortens the time of wound epithelialization. Considering the laboriousness and high cost of BCPs, the possibility of their use for the treatment of patients with neuroischemic form of DFS of various grades according to the WIfI classification should be considered.